Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding for 11 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding changed N/A to $27.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $27.6 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding for Q4 2025 was $27.6 million at Crescent Biopharma, up from $13.9 million in the prior quarter.
  • The five-year high for Shares Outstanding was $64.5 million in Q2 2024, with the low at $959384.0 in Q3 2024.
  • Average Shares Outstanding over 5 years is $45.4 million, with a median of $52.4 million recorded in 2022.
  • The sharpest move saw Shares Outstanding grew 22.79% in 2023, then crashed 98.42% in 2025.
  • Over 5 years, Shares Outstanding stood at $52.3 million in 2021, then increased by 3.95% to $54.4 million in 2022, then increased by 18.42% to $64.4 million in 2023, then grew by 0.14% to $64.5 million in 2024, then plummeted by 57.27% to $27.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $27.6 million, $13.9 million, and $13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.